Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ALTS

ALT5 Sigma Corp

Jan 13 • 04:00PM ET

5.69

Dollar change -0.63
Percentage change -9.97	%

Technology • Software - Application • USA • NASD

Peers: COIN MSTR RIOT MARA HIVE BTBT GBTC BITO BLOK SDIG

| Held by: VTI VXF IWC BSVO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-3.20	Insider Own	2.57%	Shs Outstand	14.02M	Perf Week	3.64%
Market Cap	80.06M	Forward P/E	-	EPS next Y	-	Insider Trans	2.26%	Shs Float	13.71M	Perf Month	70.87%
Income	-16.61M	PEG	-	EPS next Q	-	Inst Own	4.62%	Short Float	0.46%	Perf Quarter	225.14%
Sales	7.11M	P/S	11.26	EPS this Y	-	Inst Trans	128.18%	Short Ratio	0.31	Perf Half Y	155.16%
Book/sh	0.26	P/B	21.68	EPS next Y	-	ROA	-34.10%	Short Interest	0.06M	Perf Year	953.70%
Cash/sh	0.62	P/C	9.23	EPS next 5Y	-	ROE	-70.25%	52W Range	0.50 - 7.09	Perf YTD	22.37%
Dividend Est.	-	P/FCF	24.11	EPS past 5Y	23.21%	ROI	-52.89%	52W High	-19.75%	Beta	1.84
Dividend TTM	-	Quick Ratio	0.75	Sales past 5Y	-21.33%	Gross Margin	-4.78%	52W Low	1038.00%	ATR (14)	0.61
Dividend Ex-Date	Apr 01, 2022	Current Ratio	0.75	EPS Y/Y TTM	27.61%	Oper. Margin	-109.23%	RSI (14)	65.75	Volatility	18.61% 12.80%
Employees	5	Debt/Eq	0.47	Sales Y/Y TTM	-36.30%	Profit Margin	-233.56%	Recom	-	Target Price	-
Option/Short	No / Yes	LT Debt/Eq	0.30	EPS Q/Q	-25.88%	Payout	-	Rel Volume	1.23	Prev Close	6.32
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-	Earnings	-	Avg Volume	200.87K	Price	5.69
SMA20	20.68%	SMA50	68.23%	SMA200	106.26%	Trades		Volume	244,609	Change	-9.97%

Jan-10-25 08:30AM	Alyea Therapeutics to Present at Biotech Showcase 2025 During 43rd Annual J.P. Morgan Healthcare Conference Week (ACCESSWIRE)
Jan-09-25 11:30AM	ALT5 Sigma to Exhibit at iFX EXPO Dubai January 14-16, 2025 (ACCESSWIRE)
Dec-18-24 04:00PM	ALT5 Sigma Announces Results of 2024 AGM and Corporate Update (ACCESSWIRE) -6.13%
Nov-27-24 07:00AM	DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025 (ACCESSWIRE) +5.12%
Nov-12-24 05:23PM	ALT5 Sigma Reports Fiscal Financial Results for Third Quarter 2024 (ACCESSWIRE) +5.60%
08:30AM	Loading…
Nov-06-24 08:30AM	ALT5 Sigma Welcomes FinTech Executive, Ron Pitters to Its Board of Directors (ACCESSWIRE) +9.65%
Oct-30-24 10:30AM	ALT5 Sigma Corporation Announces Participation at the Spartan Capital Investor Conference (ACCESSWIRE)
Oct-23-24 05:00PM	ALT5 Sigma to Exhibit at Money20/20 October 27-30, 2024 (ACCESSWIRE) +6.30%
Oct-09-24 08:30AM	ALT5 Sigma Reports a Record Month at Over $240 Million in Transaction Volume (ACCESSWIRE)
Oct-02-24 08:30AM	ALT5 Announces Plan to Separate Into Two Independent Publicly Traded Companies (ACCESSWIRE)
Sep-10-24 11:00AM	ALT5 Sigma Reports 104% Year-Over-Year Increase in Transaction Volume to Over US$1.250 Billion for First Eight Months of 2024 (ACCESSWIRE)
Sep-09-24 08:00AM	ALT5 Sigma to Exhibit at iFX Bangkok September 16-18, 2024 (ACCESSWIRE)
Aug-26-24 08:45AM	ALT5 Sigma Appoints Peter Tassiopoulos as Chief Executive Officer (ACCESSWIRE) -6.69%
Aug-23-24 11:00AM	ALT 5 Sigma to Exhibit at SiGMA Budapest September 2-4, 2024 (ACCESSWIRE)
Aug-19-24 06:30PM	ALT5 Sigma Reports Fiscal Financial Results for Second Quarter 2024 (ACCESSWIRE) +28.63% -8.22%
08:30AM	Loading…
Aug-13-24 08:30AM	ALT5 Sigma Reports 114% Year-Over-Year Increase in Transaction Volume for the Month of July 2024 (ACCESSWIRE) -5.13%
Jul-25-24 08:30AM	ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024 (ACCESSWIRE)

ALT5 Sigma Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of pain and addiction. It operates under the Biotechnology and Recycling segments. The Biotechnology segment focuses on finding treatments for conditions that cause severe pain and bringing to market drugs with non-addictive pain-relieving properties. The Recycling segment is involved in a turnkey appliance recycling program. The company was founded by Edward R. Cameron in 1976 and is headquartered in Las Vegas, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Johnson Virland A	Chief Financial Officer	Dec 06 '24	Buy	3.00	3,000	9,000	3,000	Dec 10 02:54 PM
Tassiopoulos Peter	Chief Executive Officer	Sep 09 '24	Buy	2.06	5,000	10,278	420,000	Sep 11 11:57 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALTS

ALT5 Sigma Corp

Upgrade your FINVIZ experience